摘要
目的探究非瓣膜性房颤抗凝治疗中达比加群酯的运用价值。方法选取本院2018年6月至2019年6月收治的100例非瓣膜性房颤患者作为研究对象,随机分为甲组和乙组,每组50例。乙组应用常规抗凝治疗,甲组在乙组治疗基础上加入达比加群酯治疗。比较两组患者的抗凝效果及治疗前后Hcy、CRP水平等。结果甲组总有效率为98.0%,明显高于乙组的74.0%,两组比较差异有统计学意义(P<0.05);治疗前,两组患者Hcy、CRP水平比较差异无统计学意义,治疗后,两组均较治疗前改善,且甲组明显优于乙组(P<0.05)。结论对非瓣膜性房颤患者进行抗凝治疗的过程中,联合使用达比加群酯,可取得较好的抗凝效果,有助于改善患者病情,临床应用效果较好,值得临床推广。
Objective To explore the value of dabigatran etexilate in anticoagulation treatment of nonvalvular atrial fibrillation.Methods 100 patients with nonvalvular atrial fibrillation admitted to our hospital from June 2018 to June 2019 were randomly divided into group A and group B,with 50 cases in each group.Group B was treated with routine anticoagulation,group A was treated with dabigatran on the basis of group B.The anticoagulant effect,Hcy and CRP levels before and after treatment were compared between the two groups.Results The total effective rate of group A was 98.0%,which was significantly higher than that of group B of 74.0%(P<0.05).Before treatment,there was no statistically significant difference in Hcy and CRP levels between the two groups.After treatment,both groups improved compared with that before treatment,and group A was significantly better than group B(P<0.05).Conclusion In the process of anticoagulant treatment for non valvular atrial fibrillation patients,the combination of dabigatran etexilate can achieve better anticoagulant effect,help to improve the patient's condition,and have better clinical application effect,which is worthy of clinical promotion.
作者
毕静
Bi Jing(Department of Cardiology,Yangxin County People's Hospital,Huangshi City,Huangshi,Hubei,435200,China)
出处
《当代医学》
2020年第25期46-47,共2页
Contemporary Medicine
关键词
非瓣膜性房颤
抗凝治疗
达比加群酯
运用价值
Nonvalvular atrial fibrillation
Anticoagulation therapy
Dabigatran etexilate
Use value
